Clinical evaluation of a fully electronic microfluidic white blood cell analyzer
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0296344 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Jianye Sui und 9 weiteren Autor:innen. Beteiligte Einrichtung: RizLab Health, Inc., Princeton, New Jersey, United States of America. Hauptthemen laut MEDLINE: Microfluidics, Hematology. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation, Biomedical Advanced Research and Development Authority, RizLab Health Inc.
Abstract (Originalsprache)
The White Blood Cell (WBC) count is one of the key parameters signaling the health of the immune system. Abnormal WBC counts often signal a systemic insult to the body such as an underlying infection or an adverse side effect to medication. Typically, the blood collected is sent to a central lab for testing, and results come back within hours, which is often inconvenient and may delay time-sensitive diagnosis or treatment. Here, we present the CytoTracker, a fully electronic, microfluidic based instant WBC analyzer with the potential to be used at point-of-care. The CytoTracker is a lightweight, portable, affordable platform capable of quantifying WBCs within minutes using only 50 μl of blood (approximately one drop of blood). In this study, we clinically evaluated the accuracy and performance of CytoTracker in measuring WBC and granulocyte counts. A total of 210 adult patients were recruited in the study. We validated the CytoTracker against a standard benchtop analyzer (Horiba Point of Care Hematology Analyzer, ABX Micros 60). Linear dynamic ranges of 2.5 k/μl– 35 k/μl and 0.6 k/μl– 26 k/μl were achieved for total WBC count and granulocyte count with correlation coefficients of 0.97 and 0.98. In addition, we verified CytoTracker’s capability of identifying abnormal blood counts with above 90% sensitivity and specificity. The promising results of this clinical validation study demonstrate the potential for the use of the CytoTracker as a reliable and accurate point-of-care WBC analyzer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- RizLab Health, Inc., Princeton, New Jersey, United States of America.
- Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States of America.
- Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
- Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States of America.
- Department of Electrical and Computer Engineering, Rutgers University, Piscataway, New Jersey, United States of America.
ORCID-Profile: Mehdi Javanmard
Förderung
- National Science Foundation
- Biomedical Advanced Research and Development Authority
- RizLab Health Inc
Zitieren
APA
Sui, J., Lin, Z., Azizpour, S., Chen, F., Gaur, S., Keene, K., Soleimani, F., Bhowmick, T., Rafique, Z., & Javanmard, M. (2024). Clinical evaluation of a fully electronic microfluidic white blood cell analyzer. PLOS ONE. https://doi.org/10.1371/journal.pone.0296344
Vancouver
Sui J, Lin Z, Azizpour S, Chen F, Gaur S, Keene K, et al. Clinical evaluation of a fully electronic microfluidic white blood cell analyzer. PLOS ONE. 2024. doi:10.1371/journal.pone.0296344
BibTeX
@article{Sui2024,
author = {Sui, Jianye and Lin, Zhongtian and Azizpour, Shahriar and Chen, Fei and Gaur, Sunanda and Keene, Kelly and Soleimani, Farzad and Bhowmick, Tanaya and Rafique, Zubaid and Javanmard, Mehdi},
title = {Clinical evaluation of a fully electronic microfluidic white blood cell analyzer},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0296344}
}
EUVIMED